{
    "nctId": "NCT05503160",
    "briefTitle": "Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application",
    "officialTitle": "Prim\u00e4res Hormon-Sensitives Mammakarzinom: Bedarfsgerechte Optimierung Der Versorgung Durch Eine Patientenzentrierte, Digitale Anwendung",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "New Healthcare Approach",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "Quality of Life (QOL)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* primary, hormone-sensitive breast cancer\n* indication for adjuvant endocrine therapy (aromatase-inhibitor, tamoxifen, GnRH-analogue allone or in combination with tamoxifen/ aromatas inhibitor; combination of endocrine therapy with CDK 4/6-inhibitor/ antibody therapy/ radiotherapy)\n* start of endocrine therapy \\<= 3 months ago\n* patients with public health ensurance\n* patients who are legally competent and able to understand and follow instructions of the study staff\n* present informed consent\n\nExclusion Criteria:\n\n* no use of internet or digital applications\n* advanced, metastatic breast cancer\n* simultaneous serious disease\n* life expectancy \\< 2 years",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}